WaveBreak is taking a transformative approach to drug discovery, targeting the fleeting intermediates that are central to many disease pathways but have been beyond the reach of conventional drug discovery approaches.

Our first focus is on two of the most prominent unmet medical needs of our time: Neurodegeneration in Alzheimer’s disease and Parkinson’s disease.

Press Releases

August 30, 2023
WaveBreak Presents New Preclinical Data at MDS 2023 Demonstrating the Efficacy of its First-in-Class, Small-Molecule Inhibitors of Toxic Oligomers for Blocking Progression of Both α-Synuclein Oligomers and Aggregates in Models of Parkinson’s Disease
April 25, 2023
Wren Therapeutics Renamed WaveBreak, Signifying Focus on Stopping the Wave of Neurodegeneration in Parkinson’s Disease, Alzheimer’s Disease, and ALS at its Source
March 29, 2023
Wren* Presents Preclinical Data at AD/PD 2023 Demonstrating Potential of its First-in-Class, Small-Molecule Inhibitors of α-Synuclein Toxic Oligomers for the Treatment of Parkinson’s Disease
January 4, 2023
Wren* Builds Out Scientific Advisory Board for Neurodegenerative Diseases
December 8, 2022
Wren* Taps Vertex Veteran Executives and Other Leaders to Advance First-in-Class Small-Molecule Drugs into Clinical Testing for Neurodegenerative Diseases
March 4, 2022
Wren* Appoints Bart Henderson as Chief Executive Officer

* Renamed WaveBreak in 2023

Back to Top